NMPA Approval

Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets (Ⅲ)

Approval Number

国药准字H20253200

Company北京福元医药股份有限公司

Registration Date

January 14, 2025

Drug Information

Generic Name

达格列净二甲双胍缓释片(Ⅲ)

Dosage Form

片剂

Strength

达格列净5mg（以C₂₁H₂₅ClO₆计）和盐酸二甲双胍1000mg

Drug Type

化学药品

Registration Date

January 14, 2025

Company Information

Applicant Company

Company Name北京福元医药股份有限公司

Company Address

北京市通州区通州工业开发区广源东街8号

Manufacturing Company

Company Name北京福元医药股份有限公司

Company Address

北京市通州区通州工业开发区广源东街8号

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.

达格列净二甲双胍缓释片(Ⅲ) - NMPA 批准文号 | MedPath